

Joe Lombardo
Governor

Richard Whitley, MS
Director



DEPARTMENT OF
HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
Helping people. It's who we are and what we do.



Stacie Weeks,
JD MPH
Administrator

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, October 19, 2023

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP),
Drug Use Review Board

Agenda Item	Record	Notes																											
1. Call to Order and Roll Call	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Jennifer Wheeler called the meeting to order at 1:15 p.m. on October 19, 2023.</p> <p>Chairperson Wheeler took the roll.</p> <table><thead><tr><th></th><th>Present</th><th>Absent</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none">• Griffin, Karen, Senior Deputy Attorney General (SDAG)• Olsen, David, Chief of Pharmacy Services• Clemons, Roshanda, MD, Medical Director• Flowers, Ellen, Program Officer I, Pharmacy Unit <p>Magellan Rx Staff Present were as follows:</p> <ul style="list-style-type: none">• Mishra, Raj, Pharm.D., Clinical Account Manager• Kim, James, Pharm.D., Dir. Clinical Account Services• Martinez, Chris, Sr. Business Analyst <p>Managed Care Organization representatives present were as follows:</p>
	Present	Absent																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											

		<ul style="list-style-type: none"> • Lim, Luke, Pharm.D., Anthem • Crecco, Jason, Pharm.D., Health Plan of Nevada • Beranek, Thomas, Pharm.D., Silver Summit Health Plan • Tran, Jimmy, Pharm.D., Molina Healthcare <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.</p>
2. General Public Comment	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Perry Shieh, Professor of Neurology and Pediatrics at UCLA.</p> <p>Public comment was provided by Lea Case on behalf of the Nevada Psychiatric Association.</p>	
3. Administrative		
a. For Possible Action: Review and Approve Meeting Minutes from July 27, 2023.	<p>Vice-Chair Netochi Adeolokun moved to approve the minutes as presented, and Board Member Crystal Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <p style="text-align: right;">Yes No Abst.</p>	

	<ul style="list-style-type: none"> • Jennifer Wheeler, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Netochi Adeolokun, Pharm.D., Vice-Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Dave England, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
b. Status Update by DHCFP	<p>Chief of Pharmacy Services David Olsen provided five announcements.</p> <ul style="list-style-type: none"> • The division held a public hearing in August to update the reimbursement methodology for Physician Administered Drugs (PAD) through a State Plan Amendment. CMS approved the amendment last month. It will become effective December 1st. The Medicare Part B scheduled will be incorporated into the Physician Administered Drug reimbursement methodology. • Please note that this work is an addition to the PAD management project that was implemented on July 1st introduced in Nevada Medicaid first fee schedule. • The division is working on a project to support Bill SB56. The bill expands the scope of billable services and prescribing authority for that in Medicaid Provider Type 91, which is licensed pharmacist after implementation. Next year, pharmacist enrolled with Nevada Medicaid will be able to prescribe drugs used for medical assisted treatment of opioid use disorder. • There has been an organizational change. The Pharmacy and DME Units will be reporting directly to the Administrator Stacie Weeks. • Additionally, my last day with the division is today. We are bringing on a Pharmacy Director and she will start November 27th. Her name is Doctor Keiko Duncan. We are excited to have 	

	her, and it has been a pleasure of being part of these meetings for the last three years.	
4. Clinical Presentations		
a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Vyjuvek .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by Karen Morton.	
ii. Presentation of utilization and clinical information.	Dr. Raj Mishra provided the clinical background and indications for Vyjuvek. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Vyjuvek. <ul style="list-style-type: none"> • Dr. Luke Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Jason Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Thomas Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Jimmy Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. Comment was made by Chairperson Wheeler.	
iv. Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as presented by Magellan with the change in bullet 3 of the renewal request to define disease improvement, and Board Member Jim Tran seconded	

	<p>the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Hemgenix .																																						
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Hemgenix.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Hemgenix.</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.																																					

	<ul style="list-style-type: none">• Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																					
iv. Proposed adoption of updated prior authorization criteria.	Board Member Tran moved to approve the criteria as presented by Magellan, and Vice-Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
c. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Roctavian .																																						
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.																																					

	Public comment was provided by Rick Keglar, Pharmacist and Director, Payer Health Outlet, Health Outcome Liaison for BioMarin.																									
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Roctavian.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Roctavian.</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																									
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																							
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																							

	<ul style="list-style-type: none"> Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Spevigo .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Spevigo.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Spevigo.</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Comments were made by Chairperson Wheeler and Vice-Chair Adeolokun.</p>	

iv.	Proposed adoption of updated prior authorization criteria.	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Magellan with the change of moving the last bullet from receiving a live vaccine in the last 4 weeks instead of the 6 weeks, and Board Member Jessica Cate seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
e.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Evkeeza .																																						
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
ii.	Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Evkeeza.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Evkeeza.</p>																																					

	<ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. Comments were made by Vice-Chair Adeolokun.																																					
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan with the addition of contraindication to ezetimibe and Vice-Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
f. For Possible Action: Discussion and possible adoption of prior																																						

authorization criteria and/or quantity limits for Joenja .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Heidi Memmott, Medical Liaison with Farming Healthcare.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Joenja.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Joenja.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Comment was made by Board Member Castaneda.</p>	
iv. Proposed adoption of updated prior authorization criteria.	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Magellan with the change of adding prescriber attestation of palpable nodal diagnosis and/or MRI/CT on bullet 5 and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <p style="text-align: right;">Yes No Abst.</p>	

	<ul style="list-style-type: none"> • Jennifer Wheeler, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Netochi Adeolokun, Pharm.D., Vice-Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Dave England, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Daybue .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Ben Scope, Pharm D and HR Field Director at Acadia Pharmaceuticals.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Daybue.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Daybue.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	

iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. Comment was made by Board Member Castaneda.																																					
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Vice-Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
h.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Elfabrio .																																						
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																					
ii.	Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Elfabrio.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Elfabrio.</p>																																					

	<ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																					
iv. Proposed adoption of updated prior authorization criteria.	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
i. For Possible Action: Discussion and possible adoption of prior authorization criteria																																						

	and/or quantity limits for Elevidys .		
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Stephanie Kennedy, Director of Medical Managed Care with Sarepta Therapeutics.</p>	
ii.	Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Elevidys.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Elevidys.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii.	Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Comment was made by Board Member Castaneda.</p>	
iv.	Proposed adoption of updated prior authorization criteria.	<p>ViceChair Adeolokun moved to approve the criteria as presented by Magellan with the exception of bullet 4, changing that to patient has confirmed mutation of the DDG between exons 1 and 71 and excluding exons 8 and 9. Changing bullet 7 to reflect patient is ambulatory as confirmed by prescribing provider attestation and then removal of bullet 9, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in</p>	

	<div>attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
j. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Xiaflex .																																						
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<div>Telephonic and web comment was called for, and the phone lines were opened.</div> <div>No Public comment was provided.</div>																																					
ii. Presentation of utilization and clinical information.	<div>Dr. Mishra discussed the indications for Xiaflex.</div> <div>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Xiaflex.</div> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented.																																					

	<ul style="list-style-type: none">• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																					
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
k. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Qalsody .																																						
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.																																					

	Public comment was provided by Paul Isikwe, Medical Account Director with Biochem Pharma, Biogen Inc.																													
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Qalsody.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Qalsody.</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																													
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																													
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Cate moved to approve the criteria as presented by Magellan with the change of removing bullet 6 and changing renewal from 6 month to 12 months, and Vice-Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

	<ul style="list-style-type: none"> Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
I. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Skyclarys .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Jennifer Farmer CEO, the Fredericks Ataxia Research Alliance (Fara).</p> <p>Public comment was provided by Robert Jaramillo, Medical Outcomes and Value Liaison at Rialto Pharmaceuticals.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indications for Skyclarys.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Skyclarys.</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Crecco with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Comment was made by Chairperson Wheeler.</p>	

iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan with removing bullet 5 and 6, editing bullet 7 to require baseline mFARS score between 20 and 80, and changing authorization to 12 months and Board Member Cate seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
5. DUR Board Requested Reports																																							
a.	Opioid Reports: <ul style="list-style-type: none">i. Opioid Trendsii. Count of Claimsiii. Med Trendiv. Top Membersv. Top Prescribersvi. Top Pharmacy	<ul style="list-style-type: none">• Dr. Mishra presented opioid utilization reports.• Dr. Lim presented opioid utilization reports.• Dr. Bitton presented opioid utilization reports.• Dr. Beranek presented opioid utilization reports.• Dr. Tran presented opioid utilization reports. <p>Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports. The board discussed utilization and trends. No additional action taken or motions for investigative referrals.</p>																																					
b.	Standard DUR Reports: <ul style="list-style-type: none">i. Top 10 Classes by Amount Paid	<ul style="list-style-type: none">• Dr. Mishra presented Standard DUR Reports• Dr. Lim presented Standard DUR Reports.• Dr. Bitton presented Standard DUR Reports																																					

ii. Top 10 Classes by Claim Count iii. Quarterly ProDUR Paid Claims Saving Report iv. Retro DUR Initiatives v. 2022 DUR Survey	<ul style="list-style-type: none"> Dr. Beranek presented Standard DUR Reports Dr. Tran presented Standard DUR Reports. 	
6. Closing Discussion		
a. Public Comment	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
b. For Possible Action: Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for January 18, 2024. Location: Hilton Garden Inn Reno Meeting adjourned at 4:04 pm	

Attachment A – Members of the Public in Attendance

Louis Prusa	Robert Jaramillo	Shieh, Perry B.	Lori Amels	Kellyn Madden
Andi Stratton	Kellyn Madden	JSDO (Jason Douglas)	Jeana Colabianchi	Heather Avakemian
Karen Ward	Rick Kegler	Cadenhead, Alisa	Amy Aikins	Ann Nelson
Jennifer Farmer	Ben Skoog	Trey Delap	Michele Puyear	
Elyse Monroy-Marsala	Mark Rosenberg	Karen Ou	Lynda Finch	
Chris Johnson	Donna Laffey	Stephanie Kennedy	Seth Fritts	
Joseph So	Erin Canavan	Diane	Hale, Amy [JANUS]	
Elyse's recorder by Rewatch	Lea Case	Sean Staff	Heidi Memmott	
Paul Isikwe	Michael Pazirandeh	Kate Ogden	Neil Bair	
Taylor, Otis	Areli Alarcon	Michael Zarob	Carlos Rubio-Vaca	

Attachment B – Submitted Written Comment

[Parent Project Muscular Dystrophy](#)

[Reata Pharmaceuticals](#)

[Rett syndrome and Daybue](#)